Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Freddy Goldberg, Eliaschewitz"'
Autor:
Cintia Cercato, Joao Soares Felício, Luis Augusto Tavares Russo, Joao Lindolfo Cunha Borges, Joao Salles, Patricia Muskat, Teresa Bonansea, Antonio Roberto Chacra, Freddy Goldberg Eliaschewitz, Adriana Costa Forti
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 11, Iss 1, Pp 1-8 (2019)
Abstract Background Evogliptin (EVO) is a potent and selective dipeptidyl peptidase-4 inhibitor (DPP4i) developed for the treatment of type 2 diabetes mellitus (T2DM). DPP4is are known to exhibit a better glucose-lowering effect in Asians compared to
Externí odkaz:
https://doaj.org/article/c49b426383f94da3b122febe19ab0383
Autor:
Juan José Gagliardino, Rosario Arechavaleta, Freddy Goldberg Eliaschewitz, Kristy Iglay, Kimberly Brodovicz, Claudio D. Gonzalez, Shengsheng Yu, R. Ravi Shankar, Olaf Heisel, Paul Keown, Kaan Tunceli
Publikováno v:
Journal of Clinical & Translational Endocrinology, Vol 15, Iss , Pp 76-80 (2019)
Objective: To assess oral antihyperglycemic agents (OAHA) and/or statin treatment initiation in patients with type 2 diabetes (T2D) and time from diagnosis to both types of treatment initiation and intensification. Research design and methods: We rev
Externí odkaz:
https://doaj.org/article/dad7ad8d72054b25addf29d7f52d8d75
Autor:
Maurício Reis Pedrosa, Denise Reis Franco, Hannah Waisberg Gieremek, Camila Maia Vidal, Fernanda Bronzeri, Alexia de Cassia Rocha, Luis Gabriel de Carvalho Cara, Sofia Lenzi Fogo, Freddy Goldberg Eliaschewitz
Publikováno v:
Current Atherosclerosis Reports. 24:867-884
To discuss evidence supporting the use of glucagon-like peptide 1 receptor agonists (GLP-1RA) to treat obesity and their role as a cardioprotective drug. Obesity is not just a hypertrophy of the adipose tissue because it may become dysfunctional and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b04d64dea00e17fc2182dc3afc7d2bb8
https://doi.org/10.1007/s11883-022-01062-2
https://doi.org/10.1007/s11883-022-01062-2
Autor:
Kamlesh Khunti, León Litwak, Freddy Goldberg-Eliaschewitz, Shih-Te Tu, Pablo Aschner, Khadija Hafidh, Guillermo Gonzalez-Galvez, Ambika Gopalakrishnan Unnikrishnan, Khier Djaballah, Dilek Gogas Yavuz, Gagik Radikovich Galstyan
Publikováno v:
Diabetes Therapy
Introduction Trends on glycemic control and diabetes complications are known for high-income countries, but comprehensive data from low- and middle-income countries (LMIC) are lacking. Methods This is an expert opinion based on two retrospective stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8feaddf3f4cc5e46c3965ca8ea9dde6
https://doi.org/10.1007/s13300-021-00997-0
https://doi.org/10.1007/s13300-021-00997-0
Autor:
Claudio Gonzalez, R. Ravi Shankar, Paul Keown, Kristy Iglay, Kimberly G. Brodovicz, Shengsheng Yu, Rosario Arechavaleta, Kaan Tunceli, Olaf Heisel, Freddy Goldberg Eliaschewitz, Juan José Gagliardino
Publikováno v:
Journal of Clinical & Translational Endocrinology
Journal of Clinical & Translational Endocrinology, Vol 15, Iss, Pp 76-80 (2019)
Journal of Clinical & Translational Endocrinology, Vol 15, Iss, Pp 76-80 (2019)
Objective: To assess oral antihyperglycemic agents (OAHA) and/or statin treatment initiation in patients with type 2 diabetes (T2D) and time from diagnosis to both types of treatment initiation and intensification. Research design and methods: We rev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad541affb4db5d2206502cb7a99406d7
https://doi.org/10.1016/j.jcte.2019.01.002
https://doi.org/10.1016/j.jcte.2019.01.002
Autor:
Graziella Malzoni Leme, Daniela Farah, Marcelo Cunio Machado Fonseca, Freddy Goldberg Eliaschewitz
Publikováno v:
Diabetes Research and Clinical Practice. 149:47-63
Background The first treatment approach for type 2 diabetes mellitus is lifestyle change and metformin, but it is usually not sufficient. For some time, the anti-hyperglycemic classes of sulfonylureas and dipeptidyl peptidase-4 (DPP-4) inhibitors wer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8d9831297ddc8005a79adcb145bf8b4
https://doi.org/10.1016/j.diabres.2019.01.025
https://doi.org/10.1016/j.diabres.2019.01.025
Autor:
Cecilia Feder, Luciana A. Tagata, Freddy Goldberg Eliaschewitz, Juliana Baptista, Denise Reis Franco, Flávia V. Souza, Guilherme D. Visconti, Andre Gustavo Daher Vianna, Mariana T. Guimarães
Publikováno v:
Diabetes. 69
Decreasing glycemic variability (GV) is become a criterion of glycemic control and important goal in the treatment of diabetes. Despite this importance there are only a few reports on GV using continuous glucose monitoring (CGM) patients with T2D on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09553e18285bcdb8ca32db176f7fb582
https://doi.org/10.2337/db20-114-lb
https://doi.org/10.2337/db20-114-lb
Autor:
Linong Ji, Yufeng Li, Freddy Goldberg Eliaschewitz, Ming Liu, Trine V. Skjoeth, Yiming Li, Soeren Rasmussen, Ning Zu, Guoyue Yuan, Soo Lim, Yu-Yao Huang, Dong Xiaolin
Publikováno v:
Diabetes. 69
A total of 868 subjects of which 70% were Chinese and 13% Korean were randomised to once-weekly subcutaneous semaglutide 0.5 mg (n=288), 1.0 mg (n=290) or sitagliptin 100 mg (n=290) in a multiregional clinical trial. Both doses of semaglutide were su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4171436f25906e24356b73d24d890b06
https://doi.org/10.2337/db20-961-p
https://doi.org/10.2337/db20-961-p
Autor:
Teresa Bonansea, João Eduardo Nunes Salles, Patricia Muskat, João Lindolfo C. Borges, Luis Augusto Tavares Russo, João Soares Felício, Adriana Costa e Forti, Freddy Goldberg Eliaschewitz, Cintia Cercato, Antonio Roberto Chacra
Publikováno v:
Diabetology & Metabolic Syndrome
Diabetology & Metabolic Syndrome, Vol 11, Iss 1, Pp 1-8 (2019)
Diabetology & Metabolic Syndrome, Vol 11, Iss 1, Pp 1-8 (2019)
Background Evogliptin (EVO) is a potent and selective dipeptidyl peptidase-4 inhibitor (DPP4i) developed for the treatment of type 2 diabetes mellitus (T2DM). DPP4is are known to exhibit a better glucose-lowering effect in Asians compared to other et
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73bea93779f409e27754f92153e176fb
https://doi.org/10.1186/s13098-019-0505-z
https://doi.org/10.1186/s13098-019-0505-z
Autor:
Graziella Malzoni Leme, Marcelo Cunio Machado Fonseca, Daniela Farah, Freddy Goldberg Eliaschewitz
Publikováno v:
SSRN Electronic Journal.
Background: The first treatment approach for type 2 diabetes mellitus is lifestyle change and metformin, but it is usually not enough. The anti-hyperglycemic classes of sulfonylureas and dipeptidyl peptidase-4 (DPP-4) inhibitors are considered second
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::690729fb16a27c8aa7ac2b26945015e1
https://doi.org/10.2139/ssrn.3258672
https://doi.org/10.2139/ssrn.3258672